Integration of EpiSign, facial phenotyping, and likelihood ratio interpretation of clinical abnormalities in the re-classification of an ARID1B missense variant.


Journal

American journal of medical genetics. Part C, Seminars in medical genetics
ISSN: 1552-4876
Titre abrégé: Am J Med Genet C Semin Med Genet
Pays: United States
ID NLM: 101235745

Informations de publication

Date de publication:
09 2023
Historique:
received: 13 07 2023
accepted: 14 07 2023
medline: 2 10 2023
pubmed: 1 9 2023
entrez: 1 9 2023
Statut: ppublish

Résumé

Heterozygous ARID1B variants result in Coffin-Siris syndrome. Features may include hypoplastic nails, slow growth, characteristic facial features, hypotonia, hypertrichosis, and sparse scalp hair. Most reported cases are due to ARID1B loss of function variants. We report a boy with developmental delay, feeding difficulties, aspiration, recurrent respiratory infections, slow growth, and hypotonia without a clinical diagnosis, where a previously unreported ARID1B missense variant was classified as a variant of uncertain significance. The pathogenicity of this variant was refined through combined methodologies including genome-wide methylation signature analysis (EpiSign), Machine Learning (ML) facial phenotyping, and LIRICAL. Trio exome sequencing and EpiSign were performed. ML facial phenotyping compared facial images using FaceMatch and GestaltMatcher to syndrome-specific libraries to prioritize the trio exome bioinformatic pipeline gene list output. Phenotype-driven variant prioritization was performed with LIRICAL. A de novo heterozygous missense variant, ARID1B p.(Tyr1268His), was reported as a variant of uncertain significance. The ACMG classification was refined to likely pathogenic by a supportive methylation signature, ML facial phenotyping, and prioritization through LIRICAL. The ARID1B genotype-phenotype has been expanded through an extended analysis of missense variation through genome-wide methylation signatures, ML facial phenotyping, and likelihood-ratio gene prioritization.

Identifiants

pubmed: 37654076
doi: 10.1002/ajmg.c.32056
doi:

Substances chimiques

DNA-Binding Proteins 0
Transcription Factors 0
ARID1B protein, human 0

Types de publication

Case Reports Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e32056

Informations de copyright

© 2023 The Authors. American Journal of Medical Genetics Part C: Seminars in Medical Genetics published by Wiley Periodicals LLC.

Références

Am J Hum Genet. 2020 Sep 3;107(3):403-417
pubmed: 32755546
Am J Med Genet C Semin Med Genet. 2014 Sep;166C(3):276-89
pubmed: 25169814
Genes (Basel). 2021 Aug 20;12(8):
pubmed: 34440449
Genet Med. 2018 Sep;20(9):1054-1060
pubmed: 29300386
Mol Syndromol. 2012 Apr;2(6):237-244
pubmed: 22822383
Genet Med. 2019 Jun;21(6):1295-1307
pubmed: 30349098
Am J Med Genet C Semin Med Genet. 2023 Sep;193(3):e32056
pubmed: 37654076
J Mol Diagn. 2021 Jul;23(7):894-905
pubmed: 33962052
Int J Mol Sci. 2022 Jul 16;23(14):
pubmed: 35887210
Am J Hum Genet. 2022 Mar 3;109(3):457-470
pubmed: 35120630
BMC Biotechnol. 2017 Dec 19;17(1):90
pubmed: 29258477
Hum Mutat. 2015 Dec;36(12):1197-204
pubmed: 26350204
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2020 Oct 10;37(10):1154-1157
pubmed: 32924124
Brain. 2016 Nov 1;139(11):e64
pubmed: 27474218
Nat Genet. 2022 Mar;54(3):349-357
pubmed: 35145301
Front Mol Neurosci. 2018 Aug 03;11:252
pubmed: 30123105
BMC Genomics. 2015 Sep 16;16:701
pubmed: 26376624
Am J Hum Genet. 2022 Dec 1;109(12):2163-2177
pubmed: 36413997
Nat Commun. 2018 Nov 20;9(1):4885
pubmed: 30459321
Hum Mutat. 2019 Aug;40(8):1030-1038
pubmed: 31116477
Genet Med. 2021 Jun;23(6):1065-1074
pubmed: 33547396
Am J Hum Genet. 2019 Apr 4;104(4):685-700
pubmed: 30929737

Auteurs

Caitlin Forwood (C)

NSW Health Pathology Randwick Genomics, Prince of Wales Hospital, Sydney, Australia.
Centre for Clinical Genetics, Sydney Children's Hospital, Randwick, Australia.
Neuroscience Research Australia (NeuRA), University of New South Wales, Sydney, Australia.

Katie Ashton (K)

NSW Health Pathology Randwick Genomics, Prince of Wales Hospital, Sydney, Australia.

Ying Zhu (Y)

NSW Health Pathology Randwick Genomics, Prince of Wales Hospital, Sydney, Australia.

Futao Zhang (F)

NSW Health Pathology Randwick Genomics, Prince of Wales Hospital, Sydney, Australia.

Kerith-Rae Dias (KR)

Neuroscience Research Australia (NeuRA), University of New South Wales, Sydney, Australia.

Krystle Standen (K)

NSW Health Pathology Randwick Genomics, Prince of Wales Hospital, Sydney, Australia.

Carey-Anne Evans (CA)

Neuroscience Research Australia (NeuRA), University of New South Wales, Sydney, Australia.

Louise Carey (L)

NSW Health Pathology Randwick Genomics, Prince of Wales Hospital, Sydney, Australia.

Michael Cardamone (M)

Sydney Children's Hospital, Randwick, Australia.
School of Women's and Children's Health, UNSW, Sydney, Australia.

Carolyn Shalhoub (C)

Centre for Clinical Genetics, Sydney Children's Hospital, Randwick, Australia.

Hala Katf (H)

Sydney Children's Hospital, Randwick, Australia.

Carlos Riveros (C)

Bioinformatics, Hunter Medical Research Institute, Newcastle, Australia.

Tzung-Chien Hsieh (TC)

Institute for Genomic Statistics and Bioinformatics, University Hospital Bonn, Bonn, Germany.

Peter Krawitz (P)

Institute for Genomic Statistics and Bioinformatics, University Hospital Bonn, Bonn, Germany.

Peter N Robinson (PN)

JAX Center for Precision Genetics, The JAX Cancer Center, Farmington, Connecticut, USA.

Tracy Dudding-Byth (T)

Genetics of Learning Disability (GoLD) Service, Waratah, Australia.

Bekim Sadikovic (B)

London Health Sciences Centre, Verspeeten Clinical Genome Centre, Western University, London, Canada.

Jason Pinner (J)

Centre for Clinical Genetics, Sydney Children's Hospital, Randwick, Australia.
School of Women's and Children's Health, UNSW, Sydney, Australia.

Michael F Buckley (MF)

NSW Health Pathology Randwick Genomics, Prince of Wales Hospital, Sydney, Australia.

Tony Roscioli (T)

NSW Health Pathology Randwick Genomics, Prince of Wales Hospital, Sydney, Australia.
Neuroscience Research Australia (NeuRA), University of New South Wales, Sydney, Australia.
School of Clinical Medicine, UNSW, Sydney, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH